Novel Hepatitis E Vaccine Protects for at Least a Decade
A three-dose vaccine regimen prevented hepatitis E virus (HEV) infections with high efficacy in adults over the course of 10 years, a phase III trial from China found. The HEV239 vaccine, sold under the name Hecolin outside the U.S., had an efficacy rate of 83.1% (95% CI 69.4-91.4) in the study’s modified intention-to-treat analysis and […]